Isosorbide dinitrate as an effective adjunct therapy for acute urinary retention: A randomized controlled trial
BJUI Compass · 2026-07 · 7 (7)
DOI: 10.1002/bco2.70252 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift BJUI Compass, online erschienen am 27.07.2026. Verfasst von Salman Soltani und 5 weiteren Autor:innen. Beteiligte Einrichtung: Kidney Transplantation Complications Research Center Mashhad University of Medical Sciences Mashhad Iran. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mashhad University of Medical Sciences.
Abstract (Originalsprache)
Objective
To evaluate the synergistic effect and safety of sublingual isosorbide dinitrate (ISDN) to facilitate successful voiding trial after catheterization for acute urinary retention (AUR) secondary to benign prostatic hyperplasia (BPH). Material and methods In this randomized clinical trial, male patients aged ≥ 50 years presenting with first‐episode AUR secondary to BPH at our urology emergency department were enrolled during 2019–2020. Participants were randomly assigned to receive either standard therapy (α1‐blocker and 5α‐reductase inhibitor) alone ( n = 40) or in combination with daily sublingual ISDN 10 mg for 21 days ( n = 40). Primary outcomes included successful voiding post‐catheter removal as trial without catheter (TWOC) and post‐void residual (PVR) volume. Secondary outcomes included post‐treatment prostate‐specific antigen (PSA) levels and adverse events. Data were analysed using independent t ‐tests and chi‐square tests.
Results
A total of 80 men with similar baseline characteristics were enrolled (mean ages: 70.3 ± 7.97 in the ISDN group vs. 68.2 ± 8.73 years in the controls). The rate of successful TWOC was significantly higher in the ISDN plus standard therapy group compared with standard therapy alone (50.0% vs. 22.5%, p = 0.011). PVR volume decreased significantly after treatment in both groups (within‐group p < 0.001), with a greater overall reduction observed in the ISDN group ( p = 0.002). PSA levels remained stable, with no significant within‐ or between‐group differences. On multivariable logistic regression analysis, adjunctive ISDN therapy independently predicted successful TWOC (adjusted OR 3.27, 95% CI 1.23–8.70; p = 0.017). No serious adverse events were observed.
Conclusions
Adjunctive sublingual ISDN significantly improves urinary outcomes following AUR and reduces residual urine volume without increasing adverse events. This combination therapy offers a safe and effective strategy to improve the success of TWOC in patients with BPH‐related AUR.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Kidney Transplantation Complications Research Center Mashhad University of Medical Sciences Mashhad Iran.
- Department of Urology Mashhad University of Medical Sciences Mashhad Iran.
ORCID-Profile: Salman Soltani, Seyyed Parham Ahmadi
Förderung
- Mashhad University of Medical Sciences
Zitieren
APA
Soltani, S., Ghorbani, H. R., Tavakkoli, M., Sadabadi, F., Ahmadi, S. P., & Zeinali, F. (2026). Isosorbide dinitrate as an effective adjunct therapy for acute urinary retention: A randomized controlled trial. BJUI Compass, 7(7). https://doi.org/10.1002/bco2.70252
Vancouver
Soltani S, Ghorbani HR, Tavakkoli M, Sadabadi F, Ahmadi SP, Zeinali F. Isosorbide dinitrate as an effective adjunct therapy for acute urinary retention: A randomized controlled trial. BJUI Compass. 2026;7(7). doi:10.1002/bco2.70252
BibTeX
@article{Soltani2026,
author = {Soltani, Salman and Ghorbani, Hamid Reza and Tavakkoli, Mahmoud and Sadabadi, Fatemeh and Ahmadi, Seyyed Parham and Zeinali, Farid},
title = {Isosorbide dinitrate as an effective adjunct therapy for acute urinary retention: A randomized controlled trial},
journal = {BJUI Compass},
year = {2026},
volume = {7},
number = {7},
doi = {10.1002/bco2.70252}
}
EUVIMED